 Shares of gene therapy concern Rocket Pharmaceuticals have fallen 75 from their all-time high set in February 2021 with the only setback a three-month hold on one clinical trial. Although the company has conducted four secondaries since the onset of 2019, the recent secondary offering was the first dilutive event since its all-time high, save a small private placement. 